Interest of seroprevalence surveys for the epidemiological surveillance of the SARS‐CoV‐2 pandemic in African populations: Insights from the ARIACOV project in Benin

Abstract

AbstractBackgroundMany SARS‐CoV‐2 seroprevalence surveys since the end of 2020 have disqualified the first misconception that Africa had been spared by the pandemic. Through the analysis of three SARS‐CoV‐2 seroprevalence surveys carried out in Benin as part of the ARIACOV project, we argue that the integration of epidemiological serosurveillance of the SARS‐CoV‐2 infection in the national surveillance packages would be of great use to refine the understanding of the COVID‐19 pandemic in Africa.MethodsWe carried out three repeated cross‐sectional surveys in Benin: two in Cotonou, the economic capital in March and May 2021, and one in Natitingou, a semi‐rural city in the north of the country in August 2021. Total and weighted‐by‐age‐group seroprevalences were estimated and the risk factors for SARS‐CoV‐2 infection were assessed by multivariate logistic regression.ResultsIn Cotonou, a slight increase in overall age‐standardised SARS‐CoV‐2 seroprevalence from 29.77% (95% CI: 23.12%–37.41%) at the first survey to 34.86% (95% CI: 31.57%–38.30%) at the second survey was observed. In Natitingou, the globally adjusted seroprevalence was 33.34% (95% CI: 27.75%–39.44%). A trend of high risk for SARS‐CoV 2 seropositivity was observed in adults over 40 versus the young (less than 18 years old) during the first survey in Cotonou but no longer in the second survey.ConclusionsOur results show that, however, rapid organisation of preventive measures aimed at breaking the chains of transmission, they were ultimately unable to prevent a wide spread of the virus in the population. Routine serological surveillance on strategic sentinel sites and/or populations could constitute a cost‐effective compromise to better anticipate the onset of new waves and define public health strategies.